跳至主要内容
临床试验/NCT01709279
NCT01709279Unknown不适用

Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Kanazawa University2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2012年8月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
6
试验地点
2
主要终点
all cause harmful events

研究概览

简要总结

Mesenchymal stem cells have capability to differentiate into myocardium, vascular endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible ischemic heart failure patients will be proceeded intracoronary administration of autologous adipose tissue derived stromal cells by cardiac catheterization.

详细描述

The population of the ischemic heart failure patients is enormous in Japan and the only radical treatment for them is heart transplantation: however, the number of giving donor is extremely limited. Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as myocardial cell. They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In this study, the ischemic heart failure patients will undergo intracoronary administration of autologous adipose tissue derived stromal cells through cardiac catheterization.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Heart failure patients occured by prior ischemic event whose ejection fraction must be less than 40%.

排除标准

  • Complicated severe other organ disease.
  • Patient with malignancy.
  • History of chemotherapy or irradiation within 4 weeks.
  • Patient with immunodeficiency
  • Pregnancy or possibility of pregnancy
  • Candidate who are judged to be not applicable to this study by doctors.

研究组 & 干预措施

adipose tissue derived stromal cells

Other

干预措施: adipose tissue derived stromal cells dosage (Biological)

结局指标

主要结局

all cause harmful events

时间窗: 6 month

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shuichi Kaneko

Professor

Kanazawa University

研究点 (2)

Loading locations...

相似试验